SCHEMBL19736052

SCHEMBL19736052

CCOC(=O)C1=C(O)NC2CCCCN2C1=O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 11/20 0.39
GAA P10253 1/20 0.39
HPGD P15428 1/20 0.39
HSD17B10 Q99714 1/20 0.39
MAPK1 P28482 3/20 0.39
KDM4E B2RXH2 1/20 0.38
KMT2A Q03164 4/20 0.37
MEN1 O00255 3/20 0.37
TSHR P16473 1/20 0.37
CCR1 P32246 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.36
HTT P42858 1/20 0.36
MAPT P10636 2/20 0.36
ATM Q13315 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
RXFP1 Q9HBX9 1/20 0.36
LMNA P02545 3/20 0.36
ALOX15 P16050 1/20 0.35
POLB P06746 2/20 0.35
GABRA1 P14867 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14829230 0.70 CCR1 (0.47) ALDH1A1HSD17B10MAPK1KDM4EKMT2A
SCHEMBL20726604 0.68 GABRA1 (0.48) ALDH1A1GAAHSD17B10MAPK1KMT2A
SCHEMBL22216205 0.68 SMN1; SMN2 (0.43) ALDH1A1HPGDMAPK1KMT2AMEN1
SCHEMBL30329619 0.67 SMN1; SMN2 (0.43) ALDH1A1HPGDMAPK1KMT2AMEN1
SCHEMBL28425324 0.67 SMN1; SMN2 (0.43) ALDH1A1HPGDMAPK1KMT2AMEN1
SCHEMBL15255464 0.67 ALDH1A1 (0.50) ALDH1A1GAAHPGDHSD17B10
SCHEMBL15410781 0.66 MAPT (0.42) ALDH1A1GAAHPGDHSD17B10MAPK1
SCHEMBL15945561 0.66 GABRA1 (0.47) ALDH1A1HSD17B10MAPK1KMT2AMEN1
SCHEMBL14829717 0.66 GABRA1 (0.44) ALDH1A1HSD17B10MAPK1KDM4EKMT2A
SCHEMBL9637131 0.65 ALDH1A1 (0.56) ALDH1A1GAAHPGDHSD17B10KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240199609-A1 COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 NOVARTIS AG (CH) 2024-06-20 US disclosed
US-11905283-B2 Compounds and compositions for inhibiting the activity of SHP2 NOVARTIS AG (CH) 2024-02-20 US disclosed
US-20210300919-A1 COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. 2021-09-30 US disclosed
US-10934285-B2 Compounds and compositions for inhibiting the activity of SHP2 NOVARTIS AG (CH) 2021-03-02 US disclosed
US-10934285-B2 Compounds and compositions for inhibiting the activity of SHP2 NOVARTIS AG (CH) 2021-03-02 US disclosed
EP-3468972-B1 COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 NOVARTIS AG (CH) 2020-05-20 EP disclosed
EP-3468972-B1 COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 NOVARTIS AG (CH) 2020-05-20 EP disclosed
WO-2017216706-A1 COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 NOVARTIS AG (CH) 2017-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10934285-B2 Compounds and compositions for inhibiting the activity of SHP2 PTPN1, PTPN2, PTPN5 ALDH1A1 3978/4885GAA 1149/4885HPGD 4310/4885
US-11905283-B2 Compounds and compositions for inhibiting the activity of SHP2 PTPN1, PTPN2, PTPN5 ALDH1A1 3978/4885GAA 1149/4885HPGD 4310/4885
US-20240199609-A1 COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 PTPN1, PTPN2, PTPN5 ALDH1A1 3978/4885GAA 1149/4885HPGD 4310/4885
US-20210300919-A1 COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 PTPN1, PTPN2, PTPN5 ALDH1A1 3978/4885GAA 1149/4885HPGD 4310/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.